NOTCH1 Human shRNA Lentiviral Particle (Locus ID 4851)
CAT#: TL302916V
NOTCH1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
Need custom lentivirus service?
Get a free quote
CNY 11,400.00
Cited in 2 publications. |
Product images
CNY 2,950.00
CNY 1,999.00
CNY 2,700.00
Specifications
Product Data | |
Product Name | NOTCH1 Human shRNA Lentiviral Particle (Locus ID 4851) |
Locus ID | 4851 |
Synonyms | AOS5; AOVD1; hN1; TAN1 |
Vector | pGFP-C-shLenti |
Format | Lentiviral particles |
RefSeq | NM_017617, NM_017617.2, NM_017617.3, NM_017617.4, BC013208, BC039147, BC046127, BC049843, BC063597, NM_017617.5 |
Summary | This gene encodes a member of the NOTCH family of proteins. Members of this Type I transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple different domain types. Notch signaling is an evolutionarily conserved intercellular signaling pathway that regulates interactions between physically adjacent cells through binding of Notch family receptors to their cognate ligands. The encoded preproprotein is proteolytically processed in the trans-Golgi network to generate two polypeptide chains that heterodimerize to form the mature cell-surface receptor. This receptor plays a role in the development of numerous cell and tissue types. Mutations in this gene are associated with aortic valve disease, Adams-Oliver syndrome, T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and head and neck squamous cell carcinoma. [provided by RefSeq, Jan 2016] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (2)
The use of this RNAi has been cited in the following citations: |
---|
Notch pathway regulates osimertinib drug‐tolerant persistence in EGFR ‐mutated non–small‐cell lung cancer
,null,
Cancer Science
,PubMed ID 36411521
[NOTCH1]
|
Directed Differentiation of Patient-Specific Induced Pluripotent Stem Cells Identifies the Transcriptional Repression and Epigenetic Modification of NKX2-5, HAND1, and NOTCH1 in Hypoplastic Left Heart Syndrome
,null,
PLoS ONE
,PubMed ID 25050861
[NOTCH1]
|
Documents
Product Manuals |
FAQs |
SDS |